SciBase: Interim report January 1 - September 30, 2024

January - September in figures

Important events during the quarter

Important events after the end of the  period

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on November 12, 2024.

This report has been comprehensively reviewed by the Company's auditors.

For additional information, please contact:
Pia Renaudin, CEO, tel. +46732069802, e-mail: [email protected]

Certified Advisor (CA):

Carnegie Investment Bank AB (publ)
Phone: +46 (0)73 856 42 65
E-mail: [email protected]

About SciBase
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/scibase/r/interim-report-january-1---september-30--2024,c4064790

The following files are available for download:

View original content:https://www.prnewswire.co.uk/news-releases/scibase-interim-report-january-1--september-30-2024-302302262.html